SLC35E3 identified as a target of novel‑m1061‑5p via microRNA profiling of patients with cardiovascular disease

Gao,Feng; Wang,Fa‑Gang; Lyu,Ren‑Rong; Xue,Feng; Zhang,Jian; Huo,Ran

doi:10.3892/mmr.2018.8498

SLC35E3 identified as a target of novel‑m1061‑5p via microRNA profiling of patients with cardiovascular disease

Authors:
- Feng Gao
- Fa‑Gang Wang
- Ren‑Rong Lyu
- Feng Xue
- Jian Zhang
- Ran Huo
View Affiliations

Affiliations: Department of Aesthetic, Plastic and Burn Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: January 25, 2018 https://doi.org/10.3892/mmr.2018.8498
Pages: 5159-5167
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNA) are considered to be potential therapeutic targets for the treatment of various cardiovascular diseases (CVDs). To understand the underlying mechanism of miRNAs and target genes associated with CVD, deep sequencing of blood samples from three patients with CVD and three controls was performed using the Illumina HiSeq 2000 system. The results of the present study revealed that 65 abnormal hsa‑miRNAs targeted 2,784 putative genes in patients with CVD; 59 upregulated miRNAs targeted 2,401 genes and six downregulated miRNAs targeted 383 genes. In addition, a total of 49 Gene Ontology (GO) biological processes and were enriched, and the target genes of downregulated miRNAs were enriched in 12 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Most of these pathways are responsible for lipid and glycan metabolism. In particular, three downregulated miRNAs, hsa‑miR‑1268b, hsa‑miR‑1273d, hsa‑miR‑3187‑5p, were involved in a‑linolenic acid metabolism. The target genes of upregulated miRNAs were enriched in 15 KEGG pathways, mainly in the ‘neurodegenerative diseases and cancers’ class. In the present study five novel upregulated miRNAs, including m0499‑5p, m0970‑5p, m1042‑5p, m1061‑5p and m1953‑5p, and a downregulated miRNA, novel‑m1627‑5p, were identified in patients with CVD. Novel‑m1627‑5p was demonstrated to target 146 human genes. Additionally, Novel‑m1061‑5p targeted four genes, including fumarylacetoacetate hydrolase domain containing 2A, potassium voltage‑gated channel, Shaw‑related subfamily, member 4, coiled‑coil domain containing 85C and solute carrier family 35 member E3 (SLC35E3). The GO term, ‘carbohydrate derivative transport involving in biological process’, was associated with SLC35E3. Novel‑m1061‑5p in patients with CVD may repress the expression levels of SLC35E3, a member of the nucleoside sugar transporter subfamily E, which is known to cause defective glycol‑conjugation in the Golgi complex and/or the endoplasmic reticulum. Further investigation is required to understand the underlying mechanisms of the novel miRNAs. Novel‑m1061‑5p may serve as a marker for prognosis or a potential target for the treatment of CVD.

View Figures

View References

1	Bernardo BC, Ooi JY, Lin RC and McMullen JR: miRNA therapeutics: A new class of drugs with potential therapeutic applications in the heart. Future Med Chem. 7:1771–1792. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kwekkeboom RF, Lei Z, Doevendans PA, Musters RJ and Sluijter JP: Targeted delivery of miRNA therapeutics for cardiovascular diseases: Opportunities and challenges. Clin Sci (Lond). 127:351–365. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zhang Y, Wang S, Li Y, Zhang C, Xue J, Wu X and Wang C: Relationship of microRNA 616 gene polymorphism with prognosis of patients with premature coronary artery disease. Int J Clin Pharmacol Ther. 54:899–903. 2016. View Article : Google Scholar : PubMed/NCBI
4	Li HY, Zhao X, Liu YZ, Meng Z, Wang D, Yang F and Shi QW: Plasma MicroRNA-126-5p is associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris. Cell Physiol Biochem. 39:837–846. 2016. View Article : Google Scholar : PubMed/NCBI
5	Cordes KR and Srivastava D: MicroRNA regulation of cardiovascular development. Circ Res. 104:724–732. 2009. View Article : Google Scholar : PubMed/NCBI
6	Cengiz M, Yavuzer S, Kılıçkıran Avcı B, Yürüyen M, Yavuzer H, Dikici SA, Karataş ÖF, Özen M, Uzun H, Öngen Z, et al: Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. Clin Exp Hypertens. 37:643–649. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wang J, Yan Y, Song D and Liu B: Reduced plasma miR-146a is a predictor of poor coronary collateral circulation in patients with coronary artery disease. Biomed Res Int. 2016:42859422016. View Article : Google Scholar : PubMed/NCBI
8	Wang J, Yan Y, Song D, Liu L and Liu B: The association of plasma miR-155 and VCAM-1 levels with coronary collateral circulation. Biomark Med. 11:125–131. 2017. View Article : Google Scholar : PubMed/NCBI
9	Wang M, Li W, Chang GQ, Ye CS, Ou JS, Li XX, Liu Y, Cheang TY, Huang XL and Wang SM: MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. Arterioscler Thromb Vasc Biol. 31:2044–2053. 2011. View Article : Google Scholar : PubMed/NCBI
10	Hans FP, Moser M, Bode C and Grundmann S: MicroRNA regulation of angiogenesis and arteriogenesis. Trends Cardiovasc Med. 20:253–262. 2010. View Article : Google Scholar : PubMed/NCBI
11	Rubanyi GM: Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors. Mol Ther. 21:725–738. 2013. View Article : Google Scholar : PubMed/NCBI
12	Liao LX, Zhao MB, Dong X, Jiang Y, Zeng KW and Tu PF: TDB protects vascular endothelial cells against oxygen-glucose deprivation/reperfusion-induced injury by targeting miR-34a to increase Bcl-2 expression. Sci Rep. 6:379592016. View Article : Google Scholar : PubMed/NCBI
13	Huang YQ, Cai AP, Chen JY, Huang C, Li J and Feng YQ: The relationship of plasma miR-29a and oxidized low density lipoprotein with atherosclerosis. Cell Physiol Biochem. 40:1521–1528. 2016. View Article : Google Scholar : PubMed/NCBI
14	Michell DL and Vickers KC: HDL and microRNA therapeutics in cardiovascular disease. Pharmacol Ther. 168:43–52. 2016. View Article : Google Scholar : PubMed/NCBI
15	Chen B, Luo L, Zhu W, Wei X, Li S, Huang Y, Liu M and Lin X: miR-22 contributes to the pathogenesis of patients with coronary artery disease by targeting MCP-1: An observational study. Medicine (Baltimore). 95:e44182016. View Article : Google Scholar : PubMed/NCBI
16	Martin M: Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet Journal. 17:10–12. 2011. View Article : Google Scholar
17	Gordon A and Hannon GJ: Fastx-toolkit. FASTQ/A short-reads pre-processing tools. 2010.http://hannonlab.cshl.edu/fastx_toolkit
18	Friedländer MR, Chen W, Adamidi C, Maaskola J, Einspanier R, Knespel S and Rajewsky N: Discovering microRNAs from deep sequencing data using miRDeep. Nat Biotechnol. 26:407–415. 2008. View Article : Google Scholar : PubMed/NCBI
19	Langmead B, Trapnell C, Pop M and Salzberg SL: Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10:R252009. View Article : Google Scholar : PubMed/NCBI
20	Li QB and Wang J: MIREAP: microRNA discovery by deep sequencing. 2008.https://sourceforge.net/projects/mireap/
21	Kolde R: Pheatmap: pretty heatmaps. R package version 061. 2012.https://www.r-project.org/
22	Betel D, Wilson M, Gabow A, Marks DS and Sander C: The microRNA.org resource: targets and expression. Nucleic Acids Res. 36:D149–153. 2008. View Article : Google Scholar : PubMed/NCBI
23	Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE and Näär AM: MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 328:1566–1569. 2010. View Article : Google Scholar : PubMed/NCBI
24	Rayner KJ, Suárez Y, Dávalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ and Fernández-Hernando C: MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 328:1570–1573. 2010. View Article : Google Scholar : PubMed/NCBI
25	Ramírez CM, Rotllan N, Vlassov AV, Dávalos A, Li M, Goedeke L, Aranda JF, Cirera-Salinas D, Araldi E, Salerno A, et al: Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res. 112:1592–1601. 2013. View Article : Google Scholar : PubMed/NCBI
26	Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY and Srivastava D: miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
27	Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R and Olson EN: The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI
28	Ishida N and Kawakita M: Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35). Pflugers Arch. 447:768–775. 2004. View Article : Google Scholar : PubMed/NCBI
29	Song Z: Roles of the nucleotide sugar transporters (SLC35 family) in health and disease. Mol Aspects Med. 34:590–600. 2013. View Article : Google Scholar : PubMed/NCBI